FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace
The U.S. FDA is holding a public hearing to discuss the therapeutic use of psychedelic drugs as part of a Trump administration initiative to accelerate mental health treatments. The hearing focuses on safety, training, and access standards rather than the legalization of these substances.
Why it matters
This marks a significant shift in federal policy toward integrating experimental psychedelic therapies into mainstream medical practice for mental health.
The U.S. FDA is holding a public hearing on Monday to gather feedback on the potential therapeutic use of psychedelic drugs, the latest step in a months-long push by President Donald Trump's administration to speed up development of the treatments for serious mental illnesses.
The hearing is part of a broader push launched in April, when Trump ordered the U.S. Food and Drug Administration to focus on qualifying psychedelic drug programs for its priority-voucher program.
The order also directed the FDA to work with the Drug Enforcement Administration on a pathway for some patients to obtain investigational treatments under a law, which allows certain seriously ill patients to seek experimental therapies, and to increase collaboration with the Department of Veterans Affairs.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in